Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding

Ligands targeting tau for use with positron emission tomography have rapidly been developed during the past several years, enabling the in vivo study of tau pathology in patients with Alzheimer's disease and related non-Alzheimer's disease tauopathies. Several candidate compounds have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemoine, Laetitia, Leuzy, Antoine, Chiotis, Konstantinos, Rodriguez-Vieitez, Elena, Nordberg, Agneta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Special Section: State of the Field: Advances in Neuroimaging from the 2017 Alzheimer’s Imaging Consortium. (Guest Editors: Drs. David Wolk, Victor Villemagne & Bradford Dickerson)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956931/
https://www.ncbi.nlm.nih.gov/pubmed/29780868
http://dx.doi.org/10.1016/j.dadm.2018.01.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956931/
https://www.ncbi.nlm.nih.gov/pubmed/29780868
http://dx.doi.org/10.1016/j.dadm.2018.01.007

Ejemplares similares